Skeletal complications of malignancy
暂无分享,去创建一个
[1] Paul J. Williams,et al. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. , 1999, Cancer treatment reviews.
[2] G. Romieu,et al. A Dose‐Finding Study of Zoledronate in Hypercalcemic Cancer Patients , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] G. Hortobagyi,et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Spector,et al. A high incidence of vertebral fracture in women with breast cancer , 1999, British Journal of Cancer.
[5] S. Morony,et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[7] D. Wallwiener,et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.
[8] G. Hortobagyi,et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Powles,et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. , 1998, Journal of the National Cancer Institute.
[10] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[11] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Bell,et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] T. Powles. Prognostic impact of amenorrhoea after adjuvant chemotherapy. , 1998, European journal of cancer.
[14] G. Hortobagyi,et al. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. , 1998, Cancer investigation.
[15] R. Eastell,et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] S. Mochizuki,et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.
[17] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[18] P. Delmas,et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Hortobagyi,et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.
[20] H. Vloedgraven,et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. , 1996, The Journal of clinical investigation.
[21] R. Eastell,et al. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. , 1996, Cancer treatment reviews.
[22] M. Piccart,et al. Use of bisphosphonates in cancer patients. , 1996, Cancer treatment reviews.
[23] M. Robson,et al. How is androgen-dependent metastatic prostate cancer best treated? , 1996, Hematology/Oncology Clinics of North America.
[24] R. Eastell,et al. Metabolic effects of pamidronate in patients with metastatic bone disease. , 1996, British Journal of Cancer.
[25] M. Kovacs,et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.
[26] T. Powles,et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] E. Crawford,et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. , 1994, Seminars in oncology.
[28] L. Norton,et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.
[29] W. Gregory,et al. Advanced breast cancer: use of resources and cost implications. , 1993, British Journal of Cancer.
[30] T. Powles,et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] G. Bonadonna,et al. Long-term sequelae from adjuvant chemotherapy. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[32] B. Klein,et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. , 1992, Blood.
[33] J. Kanis,et al. Natural history of skeletal disease in multiple myelomatosis and treatment with clodronate , 1992 .
[34] R B Mazess,et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.
[35] J. Warwick,et al. Parathyroid hormone related protein and skeletal morbidity in breast cancer. , 1992, European journal of cancer.
[36] G. Sze,et al. Current imaging in spinal metastatic disease. , 1991, Seminars in oncology.
[37] R. I. Cantor,et al. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. , 1991, Bone.
[38] A. Hart,et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. , 1990, British Journal of Cancer.
[39] M. Takigawa. ヒト軟骨肉腫軟骨培養細胞株(HCS-2/8)。 , 1990 .
[40] R. Rubens,et al. The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.
[41] Terry L. Smith,et al. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy , 1986, Cancer.
[42] J. Ruckdeschel,et al. Early detection and treatment of spinal epidural metastases: The role of myelography , 1986, Annals of neurology.
[43] J. Kanis,et al. Generalised increase in bone resorption in carcinoma of the prostate. , 1985, British journal of urology.
[44] T. Siegal,et al. Vertebral body resection for epidural compression by malignant tumors. Results of forty-seven consecutive operative procedures. , 1985, The Journal of bone and joint surgery. American volume.
[45] M. Jamieson. Hypercalcaemia. , 1985, British medical journal.
[46] K. Bridwell,et al. Reconstructive Spinal Surgery as Palliation for Metastatic Malignancies of the Spine , 1985, Spine.
[47] K. Fan,et al. Predicting the probability of bone metastasis through histological grading of prostate carcinoma: a retrospective correlative analysis of 81 autopsy cases with antemortem transurethral resection specimen. , 1983, The Journal of urology.
[48] P. Wilkinson,et al. Chemotherapy of metastatic carcinoma of the breast. , 1980, Clinical radiology.
[49] J. Horton,et al. CLINICAL ONCOLOGY , 1978, The Ulster Medical Journal.
[50] T. Harwood. Metastatic carcinoma to the breast. , 1971, JAMA.
[51] R. Marcove,et al. The management of pathological fractures. , 1965, The Journal of trauma.
[52] O. V. Batson. THE RÔLE OF THE VERTEBRAL VEINS IN METASTATIC PROCESSES , 1942 .